FDA expands Wilate approval to children younger than 6 years with von Willebrand disease

The FDA has approved Wilate as routine prophylaxis to minimize frequency of bleeding episodes for children younger than 6 years with von Willebrand disease.Wilate (von Willebrand factor/human coagulation factor VIII complex, Octapharma), which previously received orphan drug designation for this indication in adults and children aged 6 years and older, is now the first von Willebrand factor